Tuberculosis

Jeremy Lefroy Excerpts

Thursday 7th June 2018 Commons Chamber

[Nick Herbert]

Yes. My hon. Friend is probably aware that there is a collaborative TB strategy that was introduced by the Government, urged by the all-party parliamentary group on global TB, which the hon. Member for Ealing, Southall and I co-chair. That strategy shows very promising signs. It represents exactly the kind of partnership that we need between Public Health England and NHS England. I commend the Government for having introduced that partnership.

Most people do not realise that there is no vaccine for tuberculosis. There is a child vaccine, BCG, that some of us had when we were young, but there is no adult vaccine that works for tuberculosis—and no epidemic in human history has been beaten without a vaccine. The reason there is no vaccine is that there is market failure. Unlike HIV/AIDS, this is primarily a disease of the poor. With HIV/AIDS, there were people dying in western countries as well. The pharmaceutical companies do not have a commercial incentive to invest in the new tools that we need—better drugs, better diagnostics and a vaccine. Without partnership funding that comes from the Government, and Governments around the world who can afford it, we will not develop these new tools and we will not beat TB in the requisite timeframe.

[Jeremy Lefroy (Stafford) (Con)]

I thank my right hon. Friend for all the work he does on TB. As chair of the all-party parliamentary group on malaria and neglected tropical diseases, I would like to point out that there is a malaria vaccine, which is being deployed for the first time. We are not sure how effective it is. It is clearly quite effective, but a lot more work needs to be done on it. Companies such as GSK, which is behind this vaccine, are prepared to invest in these things even though they have no commercial return from them. Let us hope that a similar approach will be taken by commercial companies and Governments in respect of TB.

[Nick Herbert]

I agree that some companies are willing to take a non-commercial view, such as Johnson & Johnson and Osaka Pharmaceuticals, but many other major pharmaceutical companies are not developing new TB tools because there is no commercial incentive. Therefore, we do need that partnership funding to make this happen.

I would argue that there are three powerful reasons for us to act: a humanitarian reason because of the number of deaths, an economic reason because of the cost to the global economy of not doing so, and a global health security reason because of the risk of drug resistance.